Which of the K/DOQI guidelines for bone disease in dialysis patients should be changed?
Gal-Moscovici
Anca
A
Division of Nephrology and Hypertension, Department of Medicine, Evanston Northwestern Healthcare, Northwestern University Feinberg School of Medicine, Evanston, Illinois 60201, USA.
Sprague
Stuart M
SM
Hutchison
Alastair J
AJ
Shah
Nirav
N
Piraino
Beth
B
Cunningham
John
J
D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002118:Calcium / Q000097:blood; D002136:Calcium, Dietary / Q000008:administration & dosage; D002908:Chronic Disease; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy*; D007674:Kidney Diseases / Q000150:complications*; D010281:Parathyroid Hormone / Q000097:blood; D010710:Phosphates / Q000097:blood; D017410:Practice Guidelines as Topic; D018167:Receptors, Calcitriol / Q000819:agonists
D050071:Bone Density Conservation Agents; D002136:Calcium, Dietary; D010281:Parathyroid Hormone; D010710:Phosphates; D018167:Receptors, Calcitriol; D002118:Calcium